Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and more.
▶︎
I’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.
▶︎
GLP-1s: Overdosing, Side Effects & Long-Term Risks | Dr. Abud Bakri & Dr. Andrew Huberman
▶︎
Chinese Stocks in Hong Kong Near Bear Market | The China Show 6/22/2026
▶︎
Eli Lilly CEO: How GLP-1s Will Reshape America
▶︎
The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
▶︎
The Next Phase Of The Obesity Drug Race
▶︎
Novo Nordisk CEO on Wegovy, Ozempic Supplies and Pricing
▶︎
Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race
▶︎
The CEO Behind Ozempic, Wegovy and Europe's Most Valuable Company
▶︎
Eli Lilly’s CEO David Ricks delves into the drivers of the healthcare industry
▶︎
Ozempic risk: could weight loss injections be fatal? | 60 Minutes Australia
▶︎
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
▶︎
Novo Nordisk CFO discusses 36% surge in sales driven by Wegovy and Ozempic
▶︎
She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
▶︎
GLP-1s Are a Lot Weirder Than Anyone Thought | The Ezra Klein Show
▶︎
Ozempic and Mounjaro Warning! What Nobody Is Telling You!
▶︎
Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
▶︎
GLP-1 Weight Loss | 10 Things I Wish I Knew Before Starting
▶︎
Peptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex Tatem
▶︎